Provided are a highly-sensitive antibody and a test reagent using the antibody.

A method for detecting an analyte according to an immunoassay method, using a carrier on which an antigen, an antibody or an antigen-binding fragment thereof is immobilized, wherein the analyte is detected with increasing detection sensitivity by using a carrier to which an antigen, an antibody or an antigen-binding fragment thereof was immobilized by adding disaccharide and sugar alcohol to a solution comprising an antigen, an antibody or an antigen-binding fragment thereof.

Embodiments disclosed herein provide a peptoid compound comprising a structure shown in Formula I and a detection chip having the peptoid compound coupled onto its surface. The peptoid compound has a strong binding ability with EpCAM protein on the surface of circulating tumor cells. The diagnostic technology of colorectal adenocarcinoma, gastric adenocarcinoma, breast cancer, ovarian cancer, lung adenocarcinoma, prostate cancer, pancreatic cancer, stem cell cancer, retinoblastoma, or primary esophageal squamous cell carcinoma based on the peptoid compound can realize rapid detection or diagnosis. In addition, the peptoid compound can be made by a simple synthesis method with high preparation efficiency and low production cost.

##STR00001##

Machine learning analysis for classifying agglutination of fluid samples. A method includes scanning a unique scannable code printed on a test card, wherein the test card comprises a negative control fluid sample, a positive control fluid sample, and a test fluid sample. The method includes capturing an image of the test card and providing the image of the test card to a machine learning algorithm configured to assess agglutination of the test fluid sample based on the image. The method includes receiving from the machine learning algorithm one or more of a qualitative analysis or a quantitative analysis of the agglutination of the test fluid sample.

A multiplexed lateral flow assay device includes an impermeable internal reservoir having an opening to receive a sample deposition. A fluid distributor pad is arranged in fluid communication with a lower surface of the internal reservoir and divides a portion of the sample deposition substantially equally among a plurality of flow paths. Lateral flow assays having a plurality of flow lines are aligned with flow paths of the distributor pad. An impermeable paper top cover has a first window arranged over the opening of the internal reservoir, and at least a second window arranged over the test results of the lateral flow assays. A housing element houses the reservoir, the distributor pad and lateral flow assays. The housing element includes an impermeable bottom cover and a spacer element arranged between the top and bottom covers and, provides a gap between the lateral flow assays and the impermeable paper top cover.

The invention provides methods of testing food for antigens that are more stable to food processing than more clinically problematic allergens from the same food. When clinically-significant allergens are disproportionately broken down by common preparation methods, the presence of certain food ingredients may be “masked” to some tests yet may still be allergenic. To prevent false negative results due to food preparation, the invention provides tests that test for specific food antigens that are selected on the basis of their stability under processing. Antigens are selected for inclusion in the test not because they are the most clinically relevant allergens, but rather because they are robust to processing (e.g., and do not denature during cooking). Tests of the invention may also test for the most clinically relevant allergens, but importantly, by testing for stable protein products/antigens, the tests report the presence of food residues even after commercial processing.

The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad disposed along a length of the base and is configured to hold the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The conjugate pad is further configured to receive the blood plasma sample. The test strip also includes a plurality of second and third antibodies that bind to ST2, and the conjugate-ST2 complexes, respectively. The plurality of second antibodies are bound to a membrane in a test location and the plurality of third antibodies are bound to the membrane in a control location.

Provided herein are structures and methods for detecting one or more analyte molecules present in a sample. In some embodiments, the one or more analyte molecules form a complex in solution with a supramolecular structure. The supramolecular structures of the complex may be detectable such that binding of the analyte molecule to a binding site of an array is detectable via one or more features of the supramolecular structure. A binding site of an array includes capture molecules to capture bound complexes to facilitate detection.

An elongated incubation trough has an indentation open toward a top end as well as a bottom. The indentation has a first receiving area to receive an elongated test strip as well as a second receiving area to receive an end section of a fluid line. The second receiving area is in fluidic communication with the first receiving area. A maximum width of the second receiving area at bottom height is greater than a maximum width of the first receiving area at bottom height.

A method for detecting a tumor cell surface marker molecule PD-L1, comprising the following steps: providing a capture screen that has antibodies capable of specifically binding to tumor cells; making a sample to be tested flow through the capture screen, such that tumor cells in the sample to be tested bind to the capture screen; fixing captured tumor cells on the capture screen; and successively using a PD-L1 primary antibody solution, a PD-L1 secondary antibody solution labeled with a fluorophore AlexaFluor 647, a pan-CK-AlexaFluor 488 primary antibody solution, a CD45 primary antibody solution and a CD45 secondary antibody solution labeled with a fluorophore AlexaFluor 568, to incubate the cells fixed on the capture screen, and then labeling all cells on the capture screen with a nuclear fluorescent dye.

A device configured to provide a value indicative of fluorescent emission from a substrate 5 having a test region is provided. The device comprises an electromagnetic radiation source configured to emit excitation radiation towards the test region to excite fluorescent emission from a fluorescent material in the test region. The electromagnetic radiation source is configured such that a variation in intensity of the excitation radiation across the test region is less than 15%. The device further comprises a sensor configured to capture a primary 10 image of the fluorescent emission, and a controller configured to modify the primary image based on calibration data and to use the modified image to obtain the value indicative of the fluorescent emission.